BDF Gestion Cuts Holdings in Edwards Lifesciences Corporation $EW

Key Points

• BDF Gestion reduced its holdings in Edwards Lifesciences Corporation by 9.8% during the second quarter, owning 44,483 shares valued at approximately $3.48 million.
• Multiple analysts have revised their price targets for Edwards Lifesciences, with Wells Fargo raising it from $84.00 to $88.00 and Mizuho increasing it from $87.00 to $95.00, while maintaining overall optimistic ratings.
• Edwards Lifesciences reported a quarterly earnings per share (EPS) of $0.67, exceeding estimates, with revenues of $1.53 billion, reflecting an 11.9% year-over-year growth.

BDF Gestion lowered its position in shares of Edwards Lifesciences Corporation (NYSE:EW - Free Report) by 9.8% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 44,483 shares of the medical research company's stock after selling 4,847 shares during the period. BDF Gestion's holdings in Edwards Lifesciences were worth $3,479,000 at the end of the most recent reporting period.

Other large investors also recently modified their holdings of the company. Arlington Trust Co LLC raised its holdings in Edwards Lifesciences by 1.2% during the first quarter. Arlington Trust Co LLC now owns 11,092 shares of the medical research company's stock valued at $804,000 after acquiring an additional 135 shares during the period. Valeo Financial Advisors LLC grew its holdings in Edwards Lifesciences by 2.8% during the 1st quarter. Valeo Financial Advisors LLC now owns 5,136 shares of the medical research company's stock valued at $372,000 after buying an additional 142 shares in the last quarter. Versant Capital Management Inc grew its holdings in Edwards Lifesciences by 9.3% during the 1st quarter. Versant Capital Management Inc now owns 1,698 shares of the medical research company's stock valued at $123,000 after buying an additional 145 shares in the last quarter. Allspring Global Investments Holdings LLC raised its position in shares of Edwards Lifesciences by 0.5% during the first quarter. Allspring Global Investments Holdings LLC now owns 30,195 shares of the medical research company's stock valued at $2,170,000 after buying an additional 145 shares during the last quarter. Finally, Kera Capital Partners Inc. lifted its holdings in shares of Edwards Lifesciences by 5.0% in the first quarter. Kera Capital Partners Inc. now owns 3,090 shares of the medical research company's stock worth $224,000 after buying an additional 148 shares in the last quarter. 79.46% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

EW has been the subject of several research analyst reports. Robert W. Baird raised their target price on shares of Edwards Lifesciences from $78.00 to $79.00 and gave the company a "neutral" rating in a research note on Friday, July 25th. Wells Fargo & Company raised their price objective on Edwards Lifesciences from $84.00 to $88.00 and gave the company an "overweight" rating in a research report on Thursday, August 7th. Mizuho boosted their target price on Edwards Lifesciences from $87.00 to $95.00 and gave the stock an "outperform" rating in a research report on Friday, July 25th. Wall Street Zen lowered Edwards Lifesciences from a "strong-buy" rating to a "buy" rating in a research note on Saturday, September 13th. Finally, Stifel Nicolaus lifted their price objective on Edwards Lifesciences from $90.00 to $95.00 and gave the stock a "buy" rating in a research note on Friday, July 25th. Three analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, eight have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $87.17.

Edwards Lifesciences Price Performance

Edwards Lifesciences stock opened at $74.39 on Friday. The firm has a 50-day moving average of $78.69 and a two-hundred day moving average of $75.51. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.68 and a quick ratio of 3.87. Edwards Lifesciences Corporation has a 1 year low of $64.00 and a 1 year high of $83.00. The stock has a market cap of $43.67 billion, a price-to-earnings ratio of 10.70, a price-to-earnings-growth ratio of 3.60 and a beta of 1.07.

Edwards Lifesciences (NYSE:EW - Get Free Report) last announced its quarterly earnings data on Thursday, July 24th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.62 by $0.05. Edwards Lifesciences had a return on equity of 15.01% and a net margin of 72.96%.The company had revenue of $1.53 billion for the quarter, compared to analysts' expectations of $1.49 billion. During the same quarter in the prior year, the firm earned $0.70 earnings per share. Edwards Lifesciences's revenue was up 11.9% compared to the same quarter last year. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. On average, research analysts forecast that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current year.

Insider Activity

In related news, insider Larry L. Wood sold 8,950 shares of Edwards Lifesciences stock in a transaction that occurred on Monday, August 18th. The shares were sold at an average price of $78.06, for a total transaction of $698,637.00. Following the transaction, the insider directly owned 206,900 shares of the company's stock, valued at $16,150,614. This trade represents a 4.15% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, VP Daniel J. Lippis sold 4,114 shares of the company's stock in a transaction on Monday, July 28th. The stock was sold at an average price of $79.46, for a total value of $326,898.44. Following the sale, the vice president owned 22,002 shares of the company's stock, valued at approximately $1,748,278.92. This represents a 15.75% decrease in their position. The disclosure for this sale can be found here. Insiders own 1.29% of the company's stock.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corporation (NYSE:EW - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.